Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Inclusion criteria : * Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit (V1), treated for at least 3 months prior to the screening visit (V1) with metformin alone or metformin and a second oral antidiabetic treatment that can be a sulfonylurea (SU), a glinide, an alpha-glucosidase inhibitor (alpha-GI), a dipeptidyl peptidase-4 (DPP-4) inhibitor or a sodium-glucose co transporter 2 (SGLT-2) inhibitor and who are not adequately controlled with this treatment. * Signed written informed consent. Exclusion criteria: * Age \< legal age of majority at the screening visit (V1). * Body mass index (BMI) \>40 kg/m² at screening. * Glycated hemoglobin A1c (HbA1c) at screening visit: * \<7.5% or \>11% for patients previously treated with metformin alone; * \<7.0% or \>10% for patients previously treated with metformin and a second oral antidiabetic treatment. * History of hypoglycemia unawareness. * History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening. * Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria within 3 months prior to screening. * Previous treatment with insulin (except for short-term treatment due to intercurrent illness at the discretion of the Investigator) within 1 year prior to screening. * History of discontinuation of a previous treatment with glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) due to safety/tolerability reasons or lack of efficacy. * Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to screening. * Use of weight loss drugs within 3 months prior to screening. * Use of any investigational drug other than specified in this protocol within 1 month or 5 half-lives, whichever is longer, prior to screening. * Within 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization. * Planned coronary, carotid, or peripheral artery revascularization procedures to be performed during the study period. * Known history of drug or alcohol abuse within 6 months prior to screening. * Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>95 mmHg. * Laboratory findings at screening visit (V1): * Amylase and/or lipase \>3 times the upper limit of normal (ULN) laboratory range. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 ULN. * Total bilirubin \>1.5 ULN (except in case of Gilbert's syndrome). * Calcitonin ≥20 pg/mL (5.9 pmol/L). * Hemoglobin \<10.5 g/dL and/or neutrophils \<1500/mm3 and/or platelets \<100 000/mm3. * Positive urine pregnancy test in female of childbearing potential. * Patient who has a severe renal function impairment with an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2 or end-stage renal disease. * History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy. * Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes). * Use of SU, glinide, alpha-GI, DPP-4 inhibitor, and SGLT-2 inhibitor after start of run-in (from V2 \[Week -4\]). * HbA1c at V4 (Week -1) : \<7.0% or \>10%. * Fasting plasma glucose \>250 mg/dL (13.9 mmol/L) at V4 (Week-1) (can be repeated once to confirm). * Metformin maximal tolerated dose \<1500 mg/day. * Amylase and/or lipase \>3 ULN at V4 (Week-1). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.